Results 151 to 160 of about 15,983 (179)
Some of the next articles are maybe not open access.
Structural basis for the inhibition of Polo-like kinase 1
Nature Structural & Molecular Biology, 2013Polo-like kinase 1 (PLK1) is a master regulator of mitosis and is considered a potential drug target for cancer therapy. PLK1 is characterized by an N-terminal kinase domain (KD) and a C-terminal Polo-box domain (PBD). The KD and PBD are mutually inhibited, but the molecular mechanisms of the autoinhibition remain unclear.
Jun, Xu +3 more
openaire +2 more sources
Polo-like kinases in cell cycle checkpoint control
Frontiers in Bioscience, 2003Recent studies from various eukaryotic model systems indicate that polo-like kinases (Plks) play an ever-increasing role in the regulation of cell cycle progression. Early genetic studies have demonstrated that Cdc5, a budding yeast counterpart of vertebrate Plks, is essential for mitosis.
Wei, Dai, Xuan, Huang, Qin, Ruan
openaire +2 more sources
A destructive role for the Polo-like kinases
Trends in Cell Biology, 1998Abstract DESCOMBES, P. and NIGG, E. A. (1998) The polo-like kinase Plx1 is required for M phase exit and destruction of mitotic regulators in Xenopus egg extracts EMBO J . 17, 1328–1335 KOTANI, S. et al . (1998) PKA and MPF-activated Polo-like kinase regulate Anaphase-Promoting Complex activity and mitosis progression Mol.
openaire +1 more source
Developing Polo-like Kinase 1 Inhibitors
Future Medicinal Chemistry, 2020Xufeng Huang +2 more
openaire +2 more sources
Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications
Journal of Drug Targeting, 2021Ilma Shakeel +2 more
exaly
Bioorthogonal Probes for Polo‐like Kinase 1 Imaging and Quantification
Angewandte Chemie - International Edition, 2011Ghyslain Budin +2 more
exaly
Targeting polo-like kinase 1 for cancer therapy
Nature Reviews Cancer, 2006Klaus Strebhardt +2 more
exaly